Enanta Pharmaceuticals (ENTA) Other Non-Current Liabilities (2012 - 2026)
Enanta Pharmaceuticals (ENTA) reported Other Non-Current Liabilities of $278000.0 for Q1 2026, up 14.4% on a YoY basis from $243000.0 in Q1 2025, and up 3.35% quarter-over-quarter from $269000.0 in Q4 2025.
Enanta Pharmaceuticals (ENTA) Other Non-Current Liabilities (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals has reported Other Non-Current Liabilities for 15 years, with the latest figure at $278000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities rose 14.4% year-over-year to $278000.0; the trailing twelve-month figure through Mar 2026 stood at $278000.0 (up 14.4% YoY), and the FY2025 full-year result was $260000.0, up 12.55% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $278000.0, up from $269000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $1.4 million in Q3 2022, with the low at $224000.0 in Q1 2024.
- Historically, Other Non-Current Liabilities has averaged $450705.9 across 5 years, with a median of $278000.0 in 2026.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities jumped 56.76% — and 2024, when it tumbled 83.77%.
- Enanta Pharmaceuticals' Other Non-Current Liabilities stood at $414000.0 in 2022, then surged by 56.76% to $649000.0 in 2023, then sank by 63.79% to $235000.0 in 2024, then rose by 14.47% to $269000.0 in 2025, then grew by 3.35% to $278000.0 in 2026.
- The last three Other Non-Current Liabilities figures came in at $278000.0 (Q1 2026), $269000.0 (Q4 2025), and $260000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Enanta Pharmaceuticals | 365.48 Mn | 201.71 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 278,000.00 |
| Dec 31, 2025 | 269,000.00 |
| Sep 30, 2025 | 260,000.00 |
| Jun 30, 2025 | 252,000.00 |
| Mar 31, 2025 | 243,000.00 |
| Dec 31, 2024 | 235,000.00 |
| Sep 30, 2024 | 231,000.00 |
| Jun 30, 2024 | 227,000.00 |
| Mar 31, 2024 | 224,000.00 |
| Dec 31, 2023 | 649,000.00 |
| Sep 30, 2023 | 1.42 Mn |
| Jun 30, 2023 | 426,000.00 |
| Mar 31, 2023 | 408,000.00 |
| Dec 31, 2022 | 414,000.00 |
| Sep 30, 2022 | 1.42 Mn |
| Jun 30, 2022 | 354,000.00 |
| Mar 31, 2022 | 346,000.00 |
| Dec 31, 2021 | 336,000.00 |
| Sep 30, 2021 | 1.51 Mn |
| Jun 30, 2021 | 317,000.00 |